Currently, five anti-TNF biologic agents are approved for the treatment of rheumatoid arthritis
(RA): adalimumab, infliximab, etanercept, golimumab and certolizumab pegol. Formation of …

Development of neutralizing antibodies against biotherapeutic agents administered to
prevent or treat various clinical conditions is a longstanding and growing problem faced by …

Frequent infusions of intravenous factor VIII (FVIII) are required to prevent bleeding
associated with hemophilia A. To reduce the treatment burden, recombinant FVIII with a …

Abstract African American hemophilia A (HA) patients experience a higher incidence of
neutralizing anti-factor VIII (FVIII) antibodies (“inhibitors”) vis-à-vis white patients …

A major problem in treating hemophilia A patients with therapeutic factor VIII (FVIII) is that
20% to 30% of these patients produce neutralizing anti-FVIII antibodies. These antibodies …

The development of coagulation factor VIII (FVIII) inhibitory antibodies is a serious
complication in hemophilia A (HA) patients after FVIII replacement therapy. Inhibitors render …

Inflammatory signals such as pathogen-and danger-associated molecular patterns have
been hypothesized as risk factors for the initiation of the anti–factor VIII (FVIII) immune …

Abstract Development of neutralizing Abs to blood coagulation factor VIII (FVIII) provides a
major complication in hemophilia care. In this study we explored whether modulation of the …

Introduction Soluble antigens complexed with immunoglobulin G (IgG) antibodies can
induce robust adaptive immune responses in vitro and in animal models of disease. Factor …

Studies of FVIII immunogenicity are revealing mechanisms of anti-FVIII immune responses,
suggesting new approaches to reduce the incidence of inhibitors. Rational design of FVIII …